

Edgar Filing: RITE AID CORP - Form 425

RITE AID CORP
Form 425
April 13, 2018

Filed by Rite Aid Corporation

Pursuant to Rule 425 under the Securities Act of 1933

and deemed filed pursuant to Rule 14a-12

under the Exchange Act of 1934

Subject Company: Rite Aid Corporation

Commission File No.: 001-05742

Rite Aid Corporation (the Company) distributed a letter to its supplier partners providing information about the Company's operating results for its fourth quarter and fiscal year ended March 3, 2018. A copy of that document is below:

April 12, 2018

Dear Rite Aid Supplier Partners,

Today, we released our fourth-quarter and full-year results for fiscal 2018*, which reflect how we're building critical momentum as we continue working together to create the new Rite Aid.

We made significant progress in many areas during the fourth quarter: our Retail Pharmacy Segment, which includes Rite Aid stores, delivered strong results with an increase in Adjusted EBITDA over the prior year; our Pharmacy Services Segment, which includes EnvisionRxOptions, is off to a strong start in the new commercial selling season; and shortly after the quarter ended, we successfully completed our sale of 1,932 stores to Walgreens, which is delivering significant benefits to our organization.

Edgar Filing: RITE AID CORP - Form 425

However, our most significant development was that we entered into a definitive merger agreement with Albertsons to create a truly differentiated leader in food, health and wellness. We're really excited about the merger. It makes sense for us strategically and financially and will transform Rite Aid by increasing geographic presence, adding new levers for growth and solidifying our financial strength. As a result, the merger has the potential to create compelling value for our customers

and shareholders. Our board and management believe this merger is the best, value-enhancing alternative available for the company and our shareholders.

In terms of our results, we have introduced a new metric called pro-forma Adjusted EBITDA from continuing operations. This metric takes our Adjusted EBITDA and adds the Walgreens TSA fees we would have earned if all the stores sold to Walgreens were being supported under the TSA for the entire respective period. It also adjusts for the extra week in fiscal 2017. In the fourth quarter, our pro-forma Adjusted EBITDA from continuing operations was \$173.2 million compared to \$180.8 million in the prior-year period.

In terms of these results, a key highlight was the improvement of our Retail Pharmacy Segment Adjusted EBITDA compared to the prior year, which was due in large part to stronger gross margin and good expense control. While Adjusted EBITDA in the Pharmacy Services Segment decreased during the quarter, we have already secured 200,000 new lives in our commercial and health plan businesses for the new selling season and have enrolled 188,000 new lives for Medicare Part D year-over-year as of January.

We encourage you to read the press release included below for additional information about our results.

Thanks in part to your continued support, we were able to achieve stronger results during a very busy time. We successfully enhanced **wellness+ Rewards** by introducing BonusCash rewards, which has resulted in more engagement from our best customers. In addition, we continue to drive positive results in our Wellness stores, which continue to outperform the rest of the chain in terms of same-store front-end sales and prescription count and now represent nearly two-thirds of our chain.

With momentum building in critical areas, we have tremendous confidence in our strategy for the new Rite Aid. At the same time, we are excited about the potential to accelerate this strategy by combining with Albertsons to create a leading food, health and wellness company.

We took an important step toward completing the merger with the recent expiration of the Hart-Scott-Rodino waiting period. The merger remains subject to other customary closing conditions, including the approval of Rite Aid

Edgar Filing: RITE AID CORP - Form 425

shareholders, and we will be setting a date and time for a special shareholder meeting in the coming months.

As we look to make the most of this opportunity, our most important priority is to continue providing an outstanding Rite Aid Experience. Fiscal 2018 was a year of significant change for our company, and we truly appreciate all you've done in collaborating with us to drive innovation in our stores. Thank you for your continued partnership in working with us to deliver unique and engaging experiences to our customers.

We look forward to working together in providing an even higher level of innovation, convenience and value while building even more momentum for the new Rite Aid.

Sincerely,

John Standley
Chairman and CEO

Kermit Crawford
President and COO

* Press release incorporated by reference

Press Release

For Further Information Contact:

INVESTORS:
Byron Purcell
(717) 975-5809

MEDIA:
Susan Henderson
(717) 730-7766 or investor@riteaid.com

FOR IMMEDIATE RELEASE

Rite Aid Reports Fiscal 2018 Fourth Quarter and Full Year Results

- **Fourth Quarter Net Loss from Continuing Operations of \$483.7 Million or \$0.46 Per Diluted Share, Compared to the Prior Year Fourth Quarter Net Loss of \$25.1 Million or \$0.02 Per Diluted Share**
 - **Fourth Quarter Net Loss includes \$325 million of income tax expense relating to the revaluation of the company's deferred tax assets in connection with the Tax Cuts and Jobs Act of 2017 (2017 Tax Act) and a goodwill impairment charge of \$191 million, net of tax**
-

- **Fourth Quarter Adjusted Net Loss from Continuing Operations Per Diluted Share of \$0.01, Compared to the Prior Year Fourth Quarter Adjusted Net Income Per Diluted Share of \$0.02**
- **Fourth Quarter Adjusted EBITDA from Continuing Operations of \$157.4 Million, Compared to the Prior Year Fourth Quarter Adjusted EBITDA of \$167.6 Million;**
- **Fourth Quarter Pro-forma Adjusted EBITDA from Continuing Operations of \$173.2 Million, Compared to Prior Year Fourth Quarter Pro-forma Adjusted EBITDA from Continuing Operations of \$180.8 Million**
- **Prior Year Included Benefit of 53rd Week**
- **HSR Waiting Period for Albertsons Companies, Inc. (Albertsons) Merger Expired on March 28, 2018**
- **Sale of Stores to Walgreens Boots Alliance, Inc. (WBA) Completed on March 27, 2018**

CAMP HILL, Pa. (Apr. 12, 2018) - Rite Aid Corporation (NYSE: RAD) today reported operating results for its fourth quarter and fiscal year ended March 3, 2018.

For the fourth quarter, the company reported net loss from continuing operations of \$483.7 million, or \$0.46 per diluted share, Adjusted net loss from continuing operations of \$10.3 million, or \$0.01 per diluted share, Adjusted EBITDA from continuing operations of \$157.4 million, or 2.9 percent of revenues and pro-forma Adjusted EBITDA from continuing operations of \$173.2 million.

For the fourth quarter of fiscal 2018 the company reported net income of \$767.1 million, or \$0.73 per diluted share. For the full year, the company reported net income of \$943.5 million, or \$0.90 per diluted share. Net income for the fourth quarter and the full year of fiscal 2018 includes an after-tax gain of approximately \$1.2 billion and \$1.3 billion, respectively, relating to the 1,554 and 1,651 stores and related assets sold to WBA. As of March 27, 2018, Rite Aid has completed the sale of all 1,932 stores and related assets to WBA. The transfer of the three distribution centers and related inventory is expected to begin after September 1, 2018. As a result of the proceeds received from the store sales, Rite Aid's debt related to continuing operations, net of cash, was \$2.9 billion as of March 3, 2018.

During the fourth quarter, we made significant progress in a number of areas: our Retail Pharmacy Segment delivered strong results with an increase in Adjusted EBITDA over the prior year; our Pharmacy Services Segment is off to a strong start in the new commercial selling season; shortly after the quarter ended, we completed the asset sale of 1,932 stores to WBA; and we entered into a definitive merger agreement with

Edgar Filing: RITE AID CORP - Form 425

Albertsons Companies to transform Rite Aid into a truly differentiated leader in food, health and wellness, said Rite Aid Chairman and CEO John Standley.

Rite Aid President and Chief Operating Officer Kermit Crawford added: We are pleased that we've been able to drive improved operational performance through a stabilization of reimbursement rates, improvements in drug purchasing costs and a record number of immunizations which helped us deliver a higher pharmacy margin for the quarter. These areas of our business will continue to be key priorities as we begin our new fiscal year and work together to continue building momentum.

Fourth Quarter Summary

Revenues from continuing operations for the quarter were \$5.4 billion compared to revenues from continuing operations of \$5.9 billion in the prior year's fourth quarter, a decrease of \$509.1 million or 8.6

percent. Retail Pharmacy Segment revenues were \$4.0 billion and decreased 10.1 percent compared to the prior year period primarily as a result of the extra week in the prior year's fourth quarter and a decline in same store sales. Revenues in the Pharmacy Services Segment were \$1.4 billion, a decrease of 4.3 percent compared to the prior year period, which was due to a decline in commercial business and changes in its composition of Medicare Part D membership.

Same store sales from Retail Pharmacy continuing operations for the quarter decreased 1.7 percent over the prior year, consisting of a 2.3 percent decrease in pharmacy sales and a 0.6 percent decrease in front-end sales. Pharmacy sales included an approximate 138 basis point negative impact from new generic introductions. The number of prescriptions filled in same stores, adjusted to 30-day equivalents, decreased 1.8 percent over the prior year period due in part to exclusion from certain pharmacy networks that Rite Aid participated in the prior year. Prescription sales from continuing operations accounted for 64.9 percent of total drugstore sales.

Net loss from continuing operations was \$483.7 million or \$0.46 per diluted share compared to last year's fourth quarter net loss from continuing operations of \$25.1 million or \$0.02 per diluted share. The decline in operating results was due primarily to \$325 million of income tax expense relating to the revaluation of the company's deferred tax assets as a result of the 2017 Tax Act and a charge of \$191 million, net of tax, for the impairment of goodwill related to our Pharmacy Services Segment. The effect of the goodwill impairment charge is to adjust the book value of our Pharmacy Services Segment to \$2.1 billion, which was our basis in the segment at the date of acquisition. Also impacting results was a decline in Adjusted EBITDA, higher WBA deal related costs, and higher lease termination and impairment charges, partially offset by a higher LIFO credit.

Adjusted EBITDA from continuing operations (which is reconciled to net loss from continuing operations in the attached tables) was \$157.4 million or 2.9 percent of revenues for the fourth quarter compared to \$167.6 million or 2.8 percent of revenues for the same period last year. Current quarter Adjusted EBITDA includes the benefit of \$8.2 million in TSA fees while prior year's fourth quarter Adjusted EBITDA includes the benefit of \$10.8 million from the extra week. The decline in Adjusted EBITDA was due to a decrease of \$11.3 million in the Pharmacy Services Segment, resulting primarily from the decline in revenues. Adjusted EBITDA in the Retail Pharmacy Segment was favorable to the prior year due to the stabilization of reimbursement rates and improvement in generic purchasing, offset somewhat by lower revenues. Results from continuing operations are fully burdened for corporate administration costs that support both continuing and discontinued operations. Fiscal 2018 and fiscal 2017 quarterly results from continuing operations do not include \$15.8 million and \$24.0 million of fees, respectively, that would be earned if all of the stores sold to WBA were being supported under the TSA for the entire respective period. After adjusting to reflect those fees as if they had been earned for the full period and adjusting for the extra week in fiscal 2017, Pro-forma Adjusted EBITDA for the fourth quarter of fiscal 2018 and fiscal 2017 was \$173.2 million and \$180.8 million, respectively.

In the fourth quarter, the company relocated 6 stores and remodeled 38 stores, bringing the total number of wellness stores chainwide to 1,805. During the fourth quarter, the company sold 1,554 stores to WBA and closed 19 stores, resulting in a total store count of 2,831 at the end of the fourth quarter. Wellness store count and total store count related to continuing operations was 1,651 and 2,550, respectively.

Full Year Results

For the fiscal year ended March 3, 2018, revenues from continuing operations were \$21.5 billion compared to revenues of \$22.9 billion in the prior year, a decrease of \$1.4 billion or 6.1 percent. Retail Pharmacy Segment revenues were \$15.8 billion and decreased 5.6 percent compared to the prior year

period primarily as a result of the extra week in the prior year and a decline in same store sales. Revenues in the Pharmacy Services Segment were \$5.9 billion, a decrease of 7.8 percent compared to the prior year, which was due a decline in commercial business and to the change in the composition of Medicare Part D membership.

Same store sales from continuing operations for the year decreased 2.9 percent, consisting of a 3.9 percent decrease in pharmacy sales and a 0.8 percent decrease in front end sales. Pharmacy sales included an approximate 187 basis point negative impact from new generic introductions. The number of prescriptions filled in same stores, adjusted to 30-day equivalents, decreased 1.8 percent over the prior year due in part to our exclusion from certain pharmacy networks that Rite Aid participated in the prior year. Prescription sales from continuing operations accounted for 65.9 percent of total drugstore sales.

Net loss from continuing operations for fiscal 2018 was \$349.5 million or \$0.33 per diluted share compared to last year's net income from continuing operations of \$4.1 million or \$0.00 per diluted share. The decline in operating results was due primarily to higher income tax expense relating to the revaluation of the company's deferred tax assets as a result of the 2017 Tax Act, a goodwill impairment charge in the current year, a decline in Adjusted EBITDA, higher lease termination and impairment charges, and higher WBA deal related costs, partially offset by a \$325.0 million merger termination fee from WBA and a higher LIFO credit. Adjusted net loss from continuing operations for fiscal 2018 was \$20.2 million or \$0.02 per diluted share compared to last year's Adjusted net income of \$84.5 million or \$0.08 per diluted share, driven primarily by a decline in Adjusted EBITDA.

Adjusted EBITDA from continuing operations was \$559.9 million or 2.6 percent of revenues for the year compared to \$740.1 million or 3.2 percent of revenues for last year. The decline in Adjusted EBITDA is due to a decrease of \$163.5 million in the Retail Pharmacy Segment and \$16.7 million in the Pharmacy Services Segment. The decrease in the Retail Pharmacy Segment EBITDA was primarily driven by a decline in pharmacy sales and gross profit. These declines were due to a continued reductions in reimbursement rates which the company was unable to fully offset with generic purchasing efficiencies, as well as lower script counts. The decrease in the Pharmacy Services Segment EBITDA was primarily driven by the decline in revenues. Fiscal 2018 and fiscal 2017 annual results from continuing operations do not include \$87.6 million and \$96.0 million of fees, respectively, that would be earned if all of the stores sold to WBA were being supported under the TSA. After adjusting to reflect those fees as if they had been earned for the full period and for the extra week in fiscal 2017, Pro-forma Adjusted EBITDA for fiscal 2018 and fiscal 2017 was \$647.5 million and \$825.3 million, respectively.

For the year, the company relocated 20 stores, remodeled 179 stores, expanded 3 stores, opened 3 stores, sold 1,651 stores to WBA, and closed 57 stores.

Outlook for Fiscal 2019

Rite Aid is confirming its fiscal 2019 outlook for Adjusted EBITDA and net loss and providing fiscal 2019 outlook for revenues, same store sales, capital expenditures and Adjusted net income. The company's outlook for fiscal 2019 is based on the anticipated benefits from generic drug purchasing efficiencies, a reimbursement rate environment that is somewhat more stable than fiscal 2018, TSA fees under the agreement with WBA, and other initiatives to grow sales and drive operational efficiencies. The outlook provided herein, does not reflect the impact of the pending transaction with Albertsons.

Rite Aid said it expects sales to be between \$21.7 billion and \$22.1 billion in fiscal 2019 with same store sales expected to range from an increase of 0.0 percent to an increase of 1.0 percent over fiscal 2018.

Adjusted EBITDA (which is reconciled to net loss in the attached table) is expected to be between \$615.0 million and \$675.0 million.

Net loss is expected to be between \$40.0 million and \$95.0 million.

Adjusted net income per diluted share is expected to be between \$0.02 and \$0.06.

Capital expenditures are expected to be approximately \$250 million.

Rite Aid is one of the nation's leading drugstore chains with 2,548 stores in 19 states. Information about Rite Aid, including corporate background and press releases, is available through Rite Aid's website at www.riteaid.com.

Rite Aid Merger with Albertsons

As previously announced on February 20, 2018, Rite Aid and Albertsons entered into a definitive agreement under which Albertsons will merge with Rite Aid. The boards of directors of both companies have approved the transaction, and the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired. The merger is expected to close early in the second half of calendar year 2018, subject to the approval of Rite Aid's shareholders, regulatory approvals, and other customary closing conditions.

Conference Call Broadcast

Rite Aid will hold an analyst call at 8:30 a.m. Eastern Time today with remarks by Rite Aid's management team. The call will be simulcast via the internet and can be accessed at www.riteaid.com in the conference call section of investor information. A playback of the call will also be available by telephone beginning at 12:00 p.m. Eastern Time today until 11:59 p.m. Eastern Time on April 15, 2018. The playback number is 1-855-859-2056 from within the U.S. and Canada or 1-404-537-3406 from outside the U.S. and Canada with the eight-digit reservation number 72531387.

Cautionary Statement Regarding Forward Looking Statements

Statements in this release that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Rite Aid's outlook for fiscal 2019, the pending merger (the Merger) between Rite Aid and Albertsons; the expected timing of the closing of the Merger and the subsequent closings of the sale of Rite Aid distribution centers and assets to WBA; the ability of the parties to complete the Merger considering the various closing conditions to the Merger; the ability of the parties to complete the distribution center closing considering the various closing conditions applicable to the distribution centers and related assets being transferred at such distribution center closing; the outcome of legal and regulatory matters in connection with the Merger and the sale of stores and assets of Rite Aid to WBA; the expected benefits of the transactions such as improved operations, growth potential, market profile and financial strength; the competitive ability and position of Rite Aid following completion of the proposed transactions; the ability of Rite Aid to implement new business strategies following the completion of the proposed transactions and any assumptions underlying any of the foregoing. Words such as anticipate, believe, continue, could, estimate, expect, intend, may, plan, predict, project, should, and will and variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to, our high level of indebtedness and our ability to make interest and principal payments on our debt and satisfy the other covenants contained in our debt agreements; general economic, industry, market, competitive, regulatory and political conditions; our ability to improve the operating performance of our stores in accordance with our long term strategy; the impact of private and public third-party payers continued reduction in prescription drug reimbursements and efforts to encourage mail order; our ability to manage expenses and our investments in working capital; outcomes of legal and regulatory matters; changes in legislation or regulations, including healthcare reform; our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs; risks related to the proposed transactions with WBA, including the possibility that the remaining transactions may not close, or the business of Rite Aid may suffer as a result of uncertainty surrounding the proposed transactions; risks related to the expected timing and likelihood of completion of the Merger, including the risk that the Merger may not close due to one or more closing conditions to the Merger not being satisfied or waived, such as the remaining Ohio Department of Insurance regulatory approval not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the Merger or required certain conditions, limitations or restrictions in connection with such approvals, or that the required approval of the merger agreement by the stockholders of Rite Aid was not obtained; risks related to the ability to realize the anticipated benefits of the proposed transactions with Albertsons and WBA; risks related to diverting management's or employees' attention from ongoing business operations; the risk that any announcements relating to the Merger could have adverse effects on the market price of Rite Aid's common stock, and the risk that the Merger and its announcement could have an adverse effect on the ability of Rite Aid to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; the risk that Rite Aid's stock price may decline significantly if the Merger or sale of distribution centers and related assets to WBA is not completed; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement (including circumstances requiring Rite Aid to pay Albertsons a termination fee pursuant to the merger agreement); significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed transactions; potential changes to our strategy in the event the remaining proposed transactions do not close, which may include delaying or reducing capital or other expenditures, selling assets or other operations, attempting to restructure or refinance our debt, or seeking additional capital, and other business effects. These and other risks, assumptions and uncertainties are more fully described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K and in the registration statement on Form S-4, as it may be amended, that was filed with the SEC by Albertsons on April 6, 2018 in connection with the Merger, and in other documents that we file or furnish with the Securities and Exchange Commission (the SEC), which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Rite

Aid expressly disclaims any current intention to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

Additional Information and Where to Find It

In connection with the proposed merger involving Rite Aid and Albertsons, Rite Aid and Albertsons have prepared and Albertsons has filed with the SEC on April 6, 2018 a registration statement on Form S-4 that includes a proxy statement of Rite Aid that also constitutes a prospectus of Albertsons. The registration statement is not yet final and will be amended. Rite Aid will mail the proxy statement/prospectus and a proxy card to each stockholder entitled to vote at the special meeting relating

to the proposed merger. Rite Aid and Albertsons also plan to file other relevant documents with the SEC regarding the proposed merger. INVESTORS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE, AS WELL AS OTHER DOCUMENTS FILED WITH THE SEC, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. RITE AID'S EXISTING PUBLIC FILINGS WITH THE SEC SHOULD ALSO BE READ, INCLUDING THE RISK FACTORS CONTAINED THEREIN.

Investors and security holders may obtain copies of the Form S-4, including the proxy statement/prospectus, as well as other filings containing information about Rite Aid, free of charge, from the SEC's Web site (www.sec.gov). Investors and security holders may also obtain Rite Aid's SEC filings in connection with the transaction, free of charge, from Rite Aid's Web site (www.RiteAid.com) under the link Investor Relations and then under the tab SEC Filings, or by directing a request to Rite Aid, Byron Purcell, Attention: Senior Director, Treasury Services & Investor Relations. Copies of documents filed with the SEC by Albertsons will be made available, free of charge, on Albertsons' website at www.albertsonscpanies.com.

Participants in Solicitation

Rite Aid, Albertsons and their respective directors, executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the holders of Rite Aid common stock in respect of the proposed transaction. Information regarding Rite Aid's directors and executive officers is available in its definitive proxy statement for Rite Aid's 2017 annual meeting of stockholders filed with the SEC on June 7, 2017, as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such definitive proxy statement. Information about the directors and executive officers of Albertsons is set forth in the registration statement on Form S-4, including the proxy statement/prospectus, as it may be amended, that has been filed with the SEC on April 6, 2018. Other information regarding the interests of the participants in the proxy solicitation may be included in the definitive proxy statement/prospectus when it becomes available. These documents can be obtained free of charge from the sources indicated above.

Non-Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Reconciliation of Non-GAAP Financial Measures

The company separately reports financial results on the basis of Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share, Adjusted EBITDA and Pro-Forma Adjusted EBITDA which are non-GAAP financial measures. See the attached tables for a reconciliation of Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share, Adjusted EBITDA and Pro-Forma Adjusted EBITDA to net income (loss), and net income (loss) per diluted share, which are the most directly comparable GAAP financial measures. Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share exclude amortization of EnvisionRx intangible assets, merger and acquisition-related costs, loss on debt retirements, LIFO adjustments, goodwill impairment and the Walgreens Boots Alliance, Inc. termination fee. Adjusted EBITDA is defined as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments, charges or credits for facility closing

and impairment, goodwill impairment, inventory write-downs related to store closings, debt retirements, the Walgreens Boots Alliance, Inc. termination fee, and other items (including stock-based compensation expense, merger and acquisition-related costs, severance and costs related to distribution center closures, gain or loss on sale of assets and revenue deferrals related to our customer loyalty program).

The company's management team routinely evaluates how it measures the company's financial performance. In connection with such review, the company determined that it would be beneficial to investors to reflect what the company's financial results would have been had it received all of the fees that it would have earned pursuant to the TSA Agreement with WBA for the relevant period. As a result, the company hereby introduces the non-GAAP financial measure Pro Forma Adjusted EBITDA which is defined as Adjusted EBITDA plus the fees that would have been earned under the TSA, and in order to improve comparability, Pro Forma Adjusted EBITDA further adjusts results so that periods contain the same number of weeks.

###

RITE AID CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Dollars in thousands)

(unaudited)

| | March 3, 2018 | March 4, 2017 |
|--|---------------|---------------|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 447,334 | \$ 245,410 |
| Accounts receivable, net | 1,869,100 | 1,771,126 |
| Inventories, net of LIFO reserve of \$581,090 and \$607,326 | 1,799,539 | 1,789,541 |
| Prepaid expenses and other current assets | 181,181 | 211,541 |
| Current assets held for sale | 438,137 | 1,047,670 |
| Total current assets | 4,735,291 | 5,065,288 |
| Property, plant and equipment, net | 1,431,246 | 1,526,462 |
| Goodwill | 1,421,120 | 1,682,847 |
| Other intangibles, net | 590,443 | 715,406 |
| Deferred tax assets | 594,019 | 1,505,564 |
| Other assets | 217,208 | 215,917 |
| Noncurrent assets held for sale | | 882,268 |
| Total assets | \$ 8,989,327 | \$ 11,593,752 |
| LIABILITIES AND STOCKHOLDERS EQUITY | | |
| Current liabilities: | | |
| Current maturities of long-term debt and lease financing obligations | \$ 20,761 | \$ 17,709 |
| Accounts payable | 1,651,363 | 1,613,909 |
| Accrued salaries, wages and other current liabilities | 1,231,736 | 1,340,947 |
| Current liabilities held for sale | 560,205 | 32,683 |
| Total current liabilities | 3,464,065 | 3,005,248 |
| Long-term debt, less current maturities | 3,340,099 | 3,235,888 |
| Lease financing obligations, less current maturities | 30,775 | 37,204 |
| Other noncurrent liabilities | 553,378 | 643,950 |
| Noncurrent liabilities held for sale | | 4,057,392 |
| Total liabilities | 7,388,317 | 10,979,682 |
| Commitments and contingencies | | |
| Stockholders' equity: | | |
| Common stock | 1,067,318 | 1,053,690 |
| Additional paid-in capital | 4,850,712 | 4,839,854 |
| Accumulated deficit | (4,282,471) | (5,237,157) |
| Accumulated other comprehensive loss | (34,549) | (42,317) |
| Total stockholders' equity | 1,601,010 | 614,070 |
| Total liabilities and stockholders' equity | \$ 8,989,327 | \$ 11,593,752 |

Chart 1

RITE AID CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Dollars in thousands, except per share amounts)
(unaudited)

| | Thirteen weeks ended March 3, 2018 | Fourteen weeks ended March 4, 2017 |
|---|---------------------------------------|---------------------------------------|
| Revenues | \$ 5,394,264 | \$ 5,903,385 |
| Costs and expenses: | | |
| Cost of revenues | 4,124,498 | 4,554,328 |
| Selling, general and administrative expenses | 1,181,964 | 1,253,144 |
| Lease termination and impairment charges | 47,675 | 25,575 |
| Goodwill impairment | 261,727 | |
| Interest expense | 50,603 | 53,391 |
| Gain on sale of assets, net | (5,249) | (6,261) |
| | 5,661,218 | 5,880,177 |
| (Loss) income from continuing operations before income taxes | (266,954) | 23,208 |
| Income tax expense | 216,719 | 48,262 |
| Net loss from continuing operations | (483,673) | (25,054) |
| Net income from discontinued operations, net of tax | 1,250,745 | 3,912 |
| Net income (loss) | \$ 767,072 | \$ (21,142) |
| Basic and diluted income (loss) per share: | | |
| Numerator for income (loss) per share: | | |
| Net loss from continuing operations attributable to common stockholders - basic and diluted | \$ (483,673) | \$ (25,054) |
| Net income from discontinued operations attributable to common stockholders - basic and diluted | 1,250,745 | 3,912 |
| Income (loss) attributable to common stockholders - basic and diluted | \$ 767,072 | \$ (21,142) |
| Denominator: | | |
| Basic and diluted weighted average shares | 1,053,491 | 1,045,929 |
| Basic and diluted (loss) income per share | | |
| Continuing operations | \$ (0.46) | \$ (0.02) |
| Discontinued operations | \$ 1.19 | \$ 0.00 |
| Net basic and diluted income per share | \$ 0.73 | \$ (0.02) |

Chart 2

RITE AID CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Dollars in thousands, except per share amounts)
(unaudited)

| | Fifty-two weeks ended March 3, 2018 | | Fifty-three weeks ended March 4, 2017 | |
|--|--|------------|--|------------|
| Revenues | \$ | 21,528,968 | \$ | 22,927,540 |
| Costs and expenses: | | | | |
| Cost of revenues | | 16,748,863 | | 17,862,833 |
| Selling, general and administrative expenses | | 4,651,262 | | 4,776,995 |
| Lease termination and impairment charges | | 58,765 | | 45,778 |
| Goodwill impairment | | 261,727 | | |
| Interest expense | | 202,768 | | 200,065 |
| Walgreens Boots Alliance merger termination fee | | (325,000) | | |
| Gain on sale of assets, net | | (25,872) | | (6,649) |
| | | 21,572,513 | | 22,879,022 |
| (Loss) income from continuing operations before income taxes | | (43,545) | | 48,518 |
| Income tax expense | | 305,987 | | 44,438 |
| Net (loss) income from continuing operations | | (349,532) | | 4,080 |
| Net income (loss) from discontinued operations, net of tax | | 1,293,002 | | (27) |
| Net income | \$ | 943,470 | \$ | 4,053 |
| Basic and diluted (loss) income per share: | | | | |
| Numerator for income per share: | | | | |
| Net (loss) income from continuing operations attributable to common stockholders - basic and diluted | \$ | (349,532) | \$ | 4,080 |
| Net income (loss) from discontinued operations attributable to common stockholders - basic and diluted | | 1,293,002 | | (27) |
| Income attributable to common stockholders - basic and diluted | \$ | 943,470 | \$ | 4,053 |
| Denominator: | | | | |
| Basic weighted average shares | | 1,049,628 | | 1,044,427 |
| Outstanding options and restricted shares, net | | | | 16,399 |
| Diluted weighted average shares | | 1,049,628 | | 1,060,826 |
| Basic income (loss) per share | | | | |
| Continuing operations | \$ | (0.33) | \$ | 0.00 |
| Discontinued operations | \$ | 1.23 | \$ | (0.00) |
| Net basic income per share | \$ | 0.90 | \$ | 0.00 |
| Diluted income (loss) per share | | | | |
| Continuing operations | \$ | (0.33) | \$ | 0.00 |
| Discontinued operations | \$ | 1.23 | \$ | (0.00) |
| Net diluted income per share | \$ | 0.90 | \$ | 0.00 |

Chart 3

RITE AID CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

(unaudited)

| | Thirteen weeks ended March 3, 2018 | Fourteen weeks ended March 4, 2017 |
|--|---|---|
| Net income (loss) | \$ 767,072 | \$ (21,142) |
| Other comprehensive income: | | |
| Defined benefit pension plans: | | |
| Amortization of prior service cost, net transition obligation and net actuarial losses included in net periodic pension cost, net of \$3,816 and \$2,247 tax expense | 5,712 | 3,421 |
| Adjustment for implementation of ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income | 513 | |
| Total other comprehensive income | 6,225 | 3,421 |
| Comprehensive income (loss) | \$ 773,297 | \$ (17,721) |

Chart 4

RITE AID CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

(unaudited)

| | Fifty-two weeks ended March 3, 2018 | Fifty-three weeks ended March 4, 2017 |
|--|--|--|
| Net income | \$ 943,470 | \$ 4,053 |
| Other comprehensive income: | | |
| Defined benefit pension plans: | | |
| Amortization of prior service cost, net transition obligation and net actuarial losses included in net periodic pension cost, net of \$4,842 and \$3,600 tax expense | 7,255 | 5,464 |
| Adjustment for implementation of ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income | 513 | |
| Total other comprehensive income | 7,768 | 5,464 |
| Comprehensive income | \$ 951,238 | \$ 9,517 |

Chart 5

RITE AID CORPORATION AND SUBSIDIARIES

SUPPLEMENTAL SEGMENT OPERATING INFORMATION

(Dollars in thousands)

(unaudited)

| | Thirteen weeks ended March 3, 2018 | Fourteen weeks ended March 4, 2017 |
|--|---------------------------------------|---------------------------------------|
| Retail Pharmacy Segment | | |
| Revenues from continuing operations (a) | \$ 3,999,430 | \$ 4,447,175 |
| Cost of revenues from continuing operations (a) | 2,830,327 | 3,201,466 |
| Gross profit from continuing operations | 1,169,103 | 1,245,709 |
| LIFO credit from continuing operations | (49,220) | (28,987) |
| FIFO gross profit from continuing operations | 1,119,883 | 1,216,722 |
| Gross profit as a percentage of revenues - continuing operations | 29.23% | 28.01% |
| LIFO credit as a percentage of revenues - continuing operations | -1.23% | -0.65% |
| FIFO gross profit as a percentage of revenues - continuing operations | 28.00% | 27.36% |
| Selling, general and administrative expenses from continuing operations | 1,093,258 | 1,171,840 |
| Selling, general and administrative expenses as a percentage of revenues - continuing operations | 27.34% | 26.35% |
| Cash interest expense | 90,915 | 109,584 |
| Non-cash interest expense | 5,217 | 5,639 |
| Total interest expense | 96,132 | 115,223 |
| Interest expense - continuing operations | 50,628 | 53,433 |
| Interest expense - discontinued operations | 45,504 | 61,790 |
| Adjusted EBITDA - continuing operations | 124,107 | 122,951 |
| Adjusted EBITDA as a percentage of revenues - continuing operations | 3.10% | 2.76% |
| Pharmacy Services Segment | | |
| Revenues (a) | \$ 1,445,457 | \$ 1,510,814 |
| Cost of revenues (a) | 1,344,794 | 1,407,466 |
| Gross profit | 100,663 | 103,348 |
| Gross profit as a percentage of revenues | 6.96% | 6.84% |
| Adjusted EBITDA | 33,297 | 44,619 |
| Adjusted EBITDA as a percentage of revenues | 2.30% | 2.95% |

(a) - Revenues and cost of revenues include \$50,623 and \$54,604 of inter-segment activity for the thirteen weeks ended March 3, 2018 and the fourteen weeks ended March 4, 2017, respectively, that is eliminated in consolidation.

RITE AID CORPORATION AND SUBSIDIARIES

SUPPLEMENTAL SEGMENT OPERATING INFORMATION

(Dollars in thousands)

(unaudited)

| | Fifty-two weeks ended March 3, 2018 | Fifty-three weeks ended March 4, 2017 |
|--|--|--|
| Retail Pharmacy Segment | | |
| Revenues from continuing operations (a) | \$ 15,832,625 | \$ 16,766,620 |
| Cost of revenues from continuing operations (a) | 11,460,252 | 12,094,645 |
| Gross profit from continuing operations | 4,372,373 | 4,671,975 |
| LIFO credit from continuing operations | (28,827) | (3,721) |
| FIFO gross profit from continuing operations | 4,343,546 | 4,668,254 |
| Gross profit as a percentage of revenues - continuing operations | 27.62% | 27.86% |
| LIFO credit as a percentage of revenues - continuing operations | -0.18% | -0.02% |
| FIFO gross profit as a percentage of revenues - continuing operations | 27.43% | 27.84% |
| Selling, general and administrative expenses from continuing operations | 4,328,567 | 4,483,496 |
| Selling, general and administrative expenses as a percentage of revenues - continuing operations | 27.34% | 26.74% |
| Cash interest expense | 404,491 | 410,386 |
| Non-cash interest expense | 21,566 | 21,612 |
| Total interest expense | 426,057 | 431,998 |
| Interest expense - continuing operations | 201,756 | 200,072 |
| Interest expense - discontinued operations | 224,301 | 231,926 |
| Adjusted EBITDA - continuing operations | 388,360 | 551,816 |
| Adjusted EBITDA as a percentage of revenues - continuing operations | 2.45% | 3.29% |
| Pharmacy Services Segment | | |
| Revenues (a) | \$ 5,896,669 | \$ 6,393,884 |
| Cost of revenues (a) | 5,488,937 | 6,001,152 |
| Gross profit | 407,732 | 392,732 |
| Gross profit as a percentage of revenues | 6.91% | 6.14% |
| Adjusted EBITDA | 171,534 | 188,235 |
| Adjusted EBITDA as a percentage of revenues | 2.91% | 2.94% |

(a) - Revenues and cost of revenues include \$200,326 and \$232,964 of inter-segment activity for the fifty-two weeks ended March 3, 2018 and the fifty-three weeks ended March 4, 2017, respectively, that is eliminated in consolidation.

Chart 7

RITE AID CORPORATION AND SUBSIDIARIES
 SUPPLEMENTAL INFORMATION
 RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA
 (In thousands)
 (unaudited)

| | Thirteen weeks ended March 3, 2018 | Fourteen weeks ended March 4, 2017 |
|---|---------------------------------------|---------------------------------------|
| Reconciliation of net loss to adjusted EBITDA: | | |
| Net loss - continuing operations | \$ (483,673) | \$ (25,054) |
| Adjustments: | | |
| Interest expense | 50,603 | 53,391 |
| Income tax expense | 216,719 | 48,262 |
| Depreciation and amortization | 93,609 | 102,906 |
| LIFO credit | (49,220) | (28,987) |
| Lease termination and impairment charges | 47,675 | 25,575 |
| Goodwill impairment | 261,727 | |
| Other | 19,964 | (8,523) |
| Adjusted EBITDA - continuing operations | \$ 157,404 | \$ 167,570 |
| Percent of revenues - continuing operations | 2.92% | 2.84% |
| Pro-forma Adjustments: | | |
| Adjustment for additional week | \$ | \$ (10,800) |
| Adjustment to reflect a full TSA fee | 15,800 | 24,000 |
| Pro Forma Adjusted EBITDA - continuing operations | \$ 173,204 | \$ 180,770 |

Chart 8

RITE AID CORPORATION AND SUBSIDIARIES

SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET (LOSS) INCOME TO ADJUSTED EBITDA
(In thousands)
(unaudited)

| | Fifty-two weeks ended March 3, 2018 | Fifty-three weeks ended March 4, 2017 |
|--|--|--|
| Reconciliation of net (loss) income to adjusted EBITDA | | |
| Net (loss) income - continuing operations | \$ (349,532) | \$ 4,080 |
| Adjustments: | | |
| Interest expense | 202,768 | 200,065 |
| Income tax expense | 305,987 | 44,438 |
| Depreciation and amortization | 386,057 | 407,366 |
| LIFO credit | (28,827) | (3,721) |
| Lease termination and impairment charges | 58,765 | 45,778 |
| Goodwill impairment | 261,727 | |
| Walgreens Boots Alliance merger termination fee | (325,000) | |
| Other | 47,949 | 42,045 |
| Adjusted EBITDA - continuing operations | \$ 559,894 | \$ 740,051 |
| Percent of revenues - continuing operations | 2.60% | 3.23% |
| Pro-forma Adjustments: | | |
| Adjustment for additional week | \$ | \$ (10,800) |
| Adjustment to reflect a full TSA fee | 87,600 | 96,000 |
| Pro Forma Adjusted EBITDA - continuing operations | \$ 647,494 | \$ 825,251 |

Chart 9

RITE AID CORPORATION AND SUBSIDIARIES

SUPPLEMENTAL INFORMATION

ADJUSTED NET (LOSS) INCOME

(Dollars in thousands, except per share amounts)

(unaudited)

| | Thirteen weeks ended March 3, 2018 | Fourteen weeks ended March 4, 2017 |
|---|---|---|
| Net loss from continuing operations | \$ (483,673) | \$ (25,054) |
| Add back - Income tax expense | 216,719 | 48,262 |
| (Loss) income before income taxes - continuing operations | (266,954) | 23,208 |
| Adjustments: | | |
| Amortization of EnvisionRx intangible assets | 19,139 | 20,805 |
| LIFO credits | (49,220) | (28,987) |
| Goodwill Impairment | 261,727 | |
| Merger and Acquisition-related costs | 6,885 | 7,944 |
| Adjusted (loss) income before income taxes - continuing operations | (28,423) | 22,970 |
| Adjusted income tax (benefit) expense (a) | (18,143) | 3,160 |
| Adjusted net (loss) income from continuing operations | \$ (10,280) | 19,810 |
| Adjusted net income (loss) per diluted share - continuing operations: | | |
| Numerator for adjusted net (loss) income per diluted share: | | |
| Adjusted net (loss) income from continuing operations | \$ (10,280) | \$ 19,810 |
| Denominator: | | |
| Basic and diluted weighted average shares | 1,053,491 | 1,045,929 |
| Net loss from continuing operations per diluted share - continuing operations | \$ (0.46) | \$ (0.02) |
| Adjusted net (loss) income per diluted share - continuing operations | \$ (0.01) | \$ 0.02 |

(a) The fiscal year 2018 and 2017 annual effective tax rates, calculated using a federal rate plus a net state rate that excluded the impact of state NOLs, state credits and valuation allowance, was used for the thirteen weeks ended March 3, 2018 and the fourteen weeks ended March 4, 2017, respectively.

Chart 10

RITE AID CORPORATION AND SUBSIDIARIES

SUPPLEMENTAL INFORMATION

ADJUSTED NET (LOSS) INCOME

(Dollars in thousands, except per share amounts)

(unaudited)

| | Fifty-two weeks ended March 3, 2018 | Fifty-three weeks ended March 4, 2017 |
|--|--|--|
| Net (loss) income from continuing operations | \$ (349,532) | \$ 4,080 |
| Add back - Income tax expense | 305,987 | 44,438 |
| Income before income taxes - continuing operations | (43,545) | 48,518 |
| Adjustments: | | |
| Amortization of EnvisionRx intangible assets | 78,554 | 83,022 |
| LIFO credits | (28,827) | (3,721) |
| Goodwill Impairment | 261,727 | |
| Merger and Acquisition-related costs | 24,283 | 14,066 |
| Walgreens Boots Alliance merger termination fee | (325,000) | |
| Adjusted (loss) income before income taxes - continuing operations | (32,808) | 141,885 |
| Adjusted income tax (benefit) expense (a) | (12,570) | 57,344 |
| Adjusted net (loss) income from continuing operations | \$ (20,238) | \$ 84,541 |
| Adjusted net (loss) income per diluted share - continuing operations: | | |
| Numerator for adjusted net (loss) income per diluted share: | | |
| Adjusted net (loss) income from continuing operations | \$ (20,238) | \$ 84,541 |
| Denominator: | | |
| Basic weighted average shares | 1,049,628 | 1,044,427 |
| Outstanding options and restricted shares, net | | 16,399 |
| Diluted weighted average shares | 1,049,628 | 1,060,826 |
| Net (loss) income from continuing operations per diluted share - continuing operations | \$ (0.33) | \$ 0.00 |
| Adjusted net (loss) income per diluted share - continuing operations | \$ (0.02) | \$ 0.08 |

(a) The fiscal year 2018 and 2017 annual effective tax rates, calculated using a federal rate plus a net state rate that excluded the impact of state NOLs, state credits and valuation allowance, was used for the fifty-two weeks ended March 3, 2018 and the fifty-three weeks ended March 4, 2017, respectively.

Chart 11

RITE AID CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands)

(unaudited)

| | Thirteen weeks ended March 3, 2018 | Fourteen weeks ended March 4, 2017 |
|---|---------------------------------------|---------------------------------------|
| OPERATING ACTIVITIES: | | |
| Net income (loss) | \$ 767,072 | \$ (21,142) |
| Net income from discontinued operations, net of tax | 1,250,745 | 3,912 |
| Net loss from continuing operations | \$ (483,673) | \$ (25,054) |
| Adjustments to reconcile to net cash provided by (used in) operating activities of continuing operations: | | |
| Depreciation and amortization | 93,609 | 102,906 |
| Lease termination and impairment charges | 47,675 | 25,575 |
| Goodwill impairment | 261,727 | |
| LIFO credits | (49,220) | (28,987) |
| Gain on sale of assets, net | (5,249) | (6,261) |
| Stock-based compensation expense | 3,243 | (13,284) |
| Changes in deferred taxes | 161,814 | 28,873 |
| Excess tax benefit on stock options and restricted stock | | 3,266 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | (329,616) | (78,070) |
| Inventories | 103,566 | 77,878 |
| Accounts payable | 92,570 | (138,724) |
| Other assets and liabilities, net | 190,574 | 37,967 |
| Net cash provided by (used in) operating activities of continuing operations | 87,020 | (13,915) |
| INVESTING ACTIVITIES: | | |
| Payments for property, plant and equipment | (45,063) | (56,426) |
| Intangible assets acquired | (8,684) | (3,662) |
| Proceeds from insured loss | 612 | |
| Proceeds from dispositions of assets and investments | 8,332 | 6,635 |
| Net cash used in investing activities of continuing operations | (44,803) | (53,453) |
| FINANCING ACTIVITIES: | | |
| Net (payments to) proceeds from revolver | (920) | 50,000 |
| Principal payments on long-term debt | (2,590) | (3,860) |
| Change in zero balance cash accounts | 8,011 | 12,395 |
| Net proceeds from the issuance of common stock | 1,380 | 2,539 |
| Excess tax benefit on stock options and restricted stock | | (3,266) |
| Net cash provided by financing activities of continuing operations | 5,881 | 57,808 |
| Cash flows from discontinued operations: | | |
| Operating activities of discontinued operations | (182,832) | 74,325 |
| Investing activities of discontinued operations | 3,307,047 | (38,430) |
| Financing activities of discontinued operations | (2,894,779) | (953) |
| Net cash provided by discontinued operations | 229,436 | 34,942 |
| Increase in cash and cash equivalents | 277,534 | 25,382 |
| Cash and cash equivalents, beginning of period | 169,800 | 220,028 |
| Cash and cash equivalents, end of period | \$ 447,334 | \$ 245,410 |

Chart 12

RITE AID CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands)

(unaudited)

| | Fifty-two weeks ended March 3, 2018 | Fifty-three weeks ended March 4, 2017 |
|---|--|--|
| OPERATING ACTIVITIES: | | |
| Net income | \$ 943,470 | \$ 4,053 |
| Net income (loss) from discontinued operations, net of tax | 1,293,002 | (27) |
| Net (loss) income from continuing operations | \$ (349,532) | \$ 4,080 |
| Adjustments to reconcile to net cash provided by operating activities of continuing operations: | | |
| Depreciation and amortization | 386,057 | 407,366 |
| Lease termination and impairment charges | 58,765 | 45,778 |
| Goodwill impairment | 261,727 | |
| LIFO credits | (28,827) | (3,721) |
| Gain on sale of assets, net | (25,872) | (6,649) |
| Stock-based compensation expense | 25,793 | 23,482 |
| Changes in deferred taxes | 260,411 | 35,038 |
| Excess tax benefit on stock options and restricted stock | | (543) |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | (349,481) | (159,590) |
| Inventories | 18,835 | (49,381) |
| Accounts payable | 211,511 | 39,542 |
| Other assets and liabilities, net | 42,083 | (152,375) |
| Net cash provided by operating activities of continuing operations | 511,470 | 183,027 |
| INVESTING ACTIVITIES: | | |
| Payments for property, plant and equipment | (185,879) | (254,149) |
| Intangible assets acquired | (28,885) | (39,648) |
| Proceeds from insured loss | 4,239 | |
| Proceeds from dispositions of assets and investments | 27,586 | 16,852 |
| Net cash used in investing activities of continuing operations | (182,939) | (276,945) |
| FINANCING ACTIVITIES: | | |
| Net (payments to) proceeds from revolver | (265,000) | 330,000 |
| Principal payments on long-term debt | (9,882) | (16,588) |
| Change in zero balance cash accounts | 35,605 | 43,080 |
| Net proceeds from the issuance of common stock | 5,796 | 6,951 |
| Excess tax benefit on stock options and restricted stock | | 543 |
| Payments for taxes related to net share settlement of equity awards | (4,103) | (6,254) |
| Net cash (used in) provided by financing activities of continuing operations | (237,584) | 357,732 |
| Cash flows from discontinued operations: | | |
| Operating activities of discontinued operations | (245,126) | 49,090 |
| Investing activities of discontinued operations | 3,496,222 | (187,314) |
| Financing activities of discontinued operations | (3,140,119) | (4,651) |
| Net cash provided by (used in) discontinued operations | 110,977 | (142,875) |
| Increase in cash and cash equivalents | 201,924 | 120,939 |
| Cash and cash equivalents, beginning of period | 245,410 | 124,471 |
| Cash and cash equivalents, end of period | \$ 447,334 | \$ 245,410 |

RITE AID CORPORATION AND SUBSIDIARIES

SUPPLEMENTAL INFORMATION

RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED EBITDA GUIDANCE

YEAR ENDING MARCH 2, 2019

(In thousands)

(unaudited)

| | Guidance Range | |
|---|-----------------------|---------------|
| | Low | High |
| Total Revenues | \$ 21,700,000 | \$ 22,100,000 |
| Same store sales | 0.00% | 1.00% |
| Gross Capital Expenditures | \$ 250,000 | \$ 250,000 |
| Reconciliation of net loss to adjusted EBITDA: | | |
| Net loss | \$ (95,000) | \$ (40,000) |
| Adjustments: | | |
| Interest expense | 210,000 | 210,000 |
| Income tax benefit | (15,000) | (10,000) |
| Depreciation and amortization | 380,000 | 380,000 |
| LIFO charge | 35,000 | 35,000 |
| Loss on debt retirement | 15,000 | 15,000 |
| Store closing and impairment charges | 40,000 | 40,000 |
| Other | 45,000 | 45,000 |
| Adjusted EBITDA | \$ 615,000 | \$ 675,000 |

Chart 14

RITE AID CORPORATION AND SUBSIDIARIES

SUPPLEMENTAL INFORMATION

RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED NET INCOME GUIDANCE

YEAR ENDING MARCH 2, 2019

(In thousands)

(unaudited)

| | Guidance Range | |
|--|-----------------------|-------------|
| | Low | High |
| Net loss | \$ (95,000) | \$ (40,000) |
| Add back - Income tax benefit | (15,000) | (10,000) |
| Loss before income taxes | (110,000) | (50,000) |
| Adjustments: | | |
| Amortization of EnvisionRx intangible assets | 85,000 | 85,000 |
| LIFO charge | 35,000 | 35,000 |
| Loss on debt retirements | 15,000 | 15,000 |
| Adjusted income before adjusted income taxes | 25,000 | 85,000 |
| Adjusted income tax expense | 7,000 | 24,000 |
| Adjusted net income | \$ 18,000 | \$ 61,000 |
| Diluted adjusted net income per share | \$ 0.02 | \$ 0.06 |

Chart 15